β-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging
β-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging
复制标题
DOI：
10.2967/jnumed.115.158337
复制
发表时间：
2015-09-01
影响因子：
9.3
通讯作者：
Xing, Lei
中科院分区：
文献类型：
--
作者：
King, Martin T.;Carpenter, Colin M.;Xing, Lei
切伦科夫发光成像（CLI）可以提供高分辨率的图像F-18-FDG-亲肿瘤，但需要延长采集时间，因为低光子灵敏度。在这项研究中，我们提出了一种新的方式，称为β-放射性发光成像（β-RLI），它结合了闪烁体与γ排斥战略成像β粒子。我们在体外和体内系统中对β-RLI与CLI进行了比较评估。方法：采用体外模型，我们表征了CLI和beta-RLI的光子灵敏度和分辨率。我们还使用无黑色素（A375，UMSCC 1-Luc）和黑色素（B16 F10-Luc）细胞系进行了一系列异种移植小鼠模型的体内实验。用荧光素酶基因（Luc）转染B16 F10和UMSCC 1细胞系。CLI是在300秒内获得的，beta-RLI是使用两次10秒的收购获得的。我们将PET评估的F-18-FDG活性与β-RLI和CLI的肿瘤辐射相关联。我们还比较了无黑色素肿瘤和黑色素肿瘤的这些模式之间的肿瘤信号背景比（SBR）。结果：在体外实验中，β-RLI的光子灵敏度是CLI的560倍。然而，β-RLI的空间分辨率（4.4 mm）低于CLI（1.0 mm）。对于体内实验，F-18-FDG活性和肿瘤放射性之间的相关性对于β-RLI为0.52（P < 0.01），对于具有CLI的无黑色素病变为0.81（P = 0.01），对于具有CLI的黑色素病变为-0.08（阴性对比; P = 0.80）。13个黑色素病变中有9个的CLI的SBR小于1，尽管在所有病变中β-RLI的SBR大于1。结论：β-RLI可以在比CLI更短的时间内产生无黑色素和黑色素肿瘤的功能图像。需要进一步的工程开发来实现这种模式的全部临床潜力。
Cerenkov luminescence imaging (CLI) can provide high-resolution images of F-18-FDG-avid tumors but requires prolonged acquisition times because of low photon sensitivity. In this study, we proposed a new modality, termed beta-radioluminescence imaging (beta-RLI), which incorporates a scintillator with a gamma-rejection strategy for imaging beta particles. We performed a comparative evaluation of beta-RLI with CLI in both in vitro and in vivo systems. Methods: Using in vitro phantoms, we characterized the photon sensitivity and resolution of CLI and beta-RLI. We also conducted a series of in vivo experiments with xenograft mouse models using both amelanotic (A375, UMSCC1-Luc) and melanotic (B16F10-Luc) cell lines. The B16F10 and UMSCC1 cell lines were transfected with the luciferase gene (Luc). CLI was acquired over 300 s, and beta-RLI was acquired using two 10-s acquisitions. We correlated F-18-FDG activities, as assessed by PET, with tumor radiances for both beta-RLI and CLI. We also compared tumor signal-to-background ratios (SBRs) between these modalities for amelanotic and melanotic tumors. Results: For in vitro experiments, the photon sensitivity for beta-RLI was 560-fold greater than that for CLI. However, the spatial resolution for beta-RLI (4.4 mm) was inferior to that of CLI (1.0 mm). For in vivo experiments, correlations between F-18-FDG activity and tumor radiance were 0.52 (P < 0.01) for beta-RLI, 0.81 (P = 0.01) for amelanotic lesions with CLI, and -0.08 (negative contrast; P = 0.80) for melanotic lesions with CLI. Nine of 13 melanotic lesions had an SBR less than 1 for CLI, despite an SBR greater than 1 among all lesions for beta-RLI. Conclusion: beta-RLI can produce functional images of both amelanotic and melanotic tumors in a shorter time frame than CLI. Further engineering developments are needed to realize the full clinical potential of this modality.